Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  International Journal of Immunopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0192-0561(87)90042-7PMID 2891627
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor

  2004cited by this paper
• Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth

  2004cited by this paper
• Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor

  2004cited by this paper
• Involvement of Lyt-2 and L3T4 in activation of hapten-specific Lyt-2+ L3T4+ T-cell clones.

  1986cited by this paper
• Biosynthesis and surface expression of T8 by peripheral blood T4+ cells in vitro.

  1986cited by this paper
• Intrathymic differentiation: Some unanswered questions

  1985cited by this paper
• Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.

  1985cited by this paper
• Coexpression of T4 and T8 on peripheral blood T cells demonstrated by two-color fluorescence flow cytometry.

  1985cited by this paper
• Adriamycin and Other Anthracyclines

  1984cited by this paper
• Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.

  1984cited by this paper
• A rat anti-mouse T4 monoclonal antibody (H129.19) inhibits the proliferation of Ia-reactive T cell clones and delineates two phenotypically distinct (T4+, Lyt-2,3-, and T4-, Lyt-2,3+) subsets among anti-Ia cytolytic T cell clones.

  1984cited by this paper
• Precursors of T cell growth factor producing cells in the thymus: ontogeny, frequency, and quantitative recovery in a subpopulation of phenotypically mature thymocytes defined by monoclonal antibody GK-1.5

  1983cited by this paper
• Characterization of the Murine Antigenic Determinant, Designated L3T4a, Recognized by Monoclonal Antibody GK 1.5: Expression of L3T4a by Functional T Cell Clones Appears to Correlate Primarily with Class II MHC Antigen‐Reactivity

  1983cited by this paper
• Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.

  1983cited by this paper
• Phenotypic and functional properties of murine thymocytes. I. Precursors of cytolytic T lymphocytes and interleukin 2-producing cells are all contained within a subpopulation of “mature” thymocytes as analyzed by monoclonal antibodies and flow microfluorometry

  1982cited by this paper
• Helper cells active in the generation of cytotoxicity to a syngeneic tumor.

  1981cited by this paper
• Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.

  1980cited by this paper
• IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.

  1980cited by this paper
• Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation.

  1979cited by this paper
• In vitro induction of tumour-specific immunity. I. Development of optimal conditions for induction and assay of cytotoxic lymphocytes.

  1975cited by this paper
• Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice.

  1975cited by this paper
• Separation of mouse spleen cells by passage through columns of sephadex G-10.

  1974cited by this paper
• Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.

  1973cited by this paper
• IN VITRO INDUCTION OF TUMOR-SPECIFIC IMMUNITY

  1973cited by this paper
• Studies of allograft immunity in mice. I. Induction, development and in vitro assay of cellular immunity.

  1970cited by this paper

• Transfusable neutrophil progenitors as cellular therapy for the prevention of invasive fungal infections

  2022cites this paper
• Therapeutic effectiveness against mopc—315 plasmacytoma of low or high doses of the synthetic thymic hormone THF—γ2 in combination with an “immunomodulating” or a “non—immunomodulating” drug

  2007cites this paper
• Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers

  2005cites this paper
• Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy

  2005cites this paper
• Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers

  2005cites this paper
• Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor

  2005cites this paper
• Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy

  2004cites this paper
• Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas

  2004cites this paper
• Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan‐treated BALB/C mice bearing a large MOPC‐315 tumor

  1992cites this paper
• A synthetic thymic hormone, THF‐γ2, repairs immunodeficiency of mice cured of plasmacytoma by melphalan

  1990cites this paper
• Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.

  1989cites this paper
• Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.

  1989cites this paper
• Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.

  1989influential citation
• Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.

  1988cites this paper
• Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.

  1987cites this paper